Navigation Links
ATS Medical Announces Record Quarterly and Full Year Revenue

Fourth Quarter 2007 Revenue Increases 32% to $14.2 Million

Gross Profit Margin at 58.2% Sets Quarterly Record

MINNEAPOLIS, Feb. 25 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported financial results for the fourth quarter and full year ended December 31, 2007. Revenue for the quarter was $14.2 million, up 32.4% from $10.7 million reported in the fourth quarter of 2006.


Contributing to the strong fourth quarter revenue growth was a 166.7% increase in revenues from the Company's ATS CryoMaze(TM) cryoablation products for the treatment of cardiac arrhythmias. Revenue from this product line rose to $3.6 million. Revenue from the Company's heart valve therapy products, consisting of mechanical valves, tissue valves and repair products, was up 13.3% on a year-over-year basis to $10.3 million. The growth reflected a 13.5% increase in mechanical valve revenue. Revenue from products and services other than the Company's mechanical valves represented 33% of total revenue during the fourth quarter of 2007 compared with 21% in the fourth quarter of 2006.

Gross profit margin for the fourth quarter of 2007 set another quarterly record of 58.2% compared with 51.0% for the fourth quarter of 2006, and 56.3% for the third quarter of 2007. The prior record gross margin was 57.8% in the first quarter of 2007.

"Our strong fourth quarter revenue growth and improved gross profit demonstrate continuing progress towards our goal of leadership in cardiac surger (909)

Net proceeds from sales of common stock

and warrants 31,196 123

Other 168 -

Net cash provided by financing activities 37,637 714

Other items (203) 544

Increase (decrease) in cash and

cash equivalents $5,868 ($12,008)

ATS Medical, Inc.

Selected Revenue Information

(in thousands)

Revenue for the Three Months Revenue for the Year

Ended December 31, Ended December 31,

2007 2006 2007 2006

Heart valve therapy $10,336 $9,122 $38,558 $35,343

Surgical arrhythmias 3,576 1,341 9,689 4,554

Surgical tools &

accessories 305 277 1,340 552

Total revenue $14,217 $10,740 $49,587 $40,449

y by advancing the standards in the treatment of heart valve disease and cardiac arrhythmias," said Michael Dale, Chairman, President and Chief Executive Officer. "We have made substantial progress in diversifying our cardiac surgery offerings, while continuing to grow our mechanical heart valve franchise. We are particularly pleased by the increased revenue contribution of our new product lines designed to treat atrial fibrillation and heart valve repair therapies."

Recent and Upcoming New Product Highlights

Surgical Arrhythmias

-- Dr. James Cox -- Effective January 1, 2008, Dr. Cox joined ATS Medical

as Medical Director. Dr. Cox is a world renowned cardiac surgeon and

is regarded as a leading expert in the treatment of atrial

fibrillation. During his illustrious career he developed the original

cut-and-sew Maze procedure. The original Maze procedure is considered

the 'Gold Standard' solution for clinical success in the treatment of

atrial fibrillation due to the >90% freedom from atrial fibrillation

at fifteen years of follow-up. Dr. Cox is leading ATS in the quest to

bring the long-term clinical success of his Maze procedure to a

minimally invasive approach through the development of new tools and

clinical techniques that leverage the ATS CryoMaze technology.

-- ATS CryoMaze surgical ablation probes and clamps -- Several new

products are under development to enhance the utility of the Company's

existing products and tools for the treatment of atrial fibrillation.

The Company anticipates launching a next generation ablation clamp and

probe in mid 2008.

-- Stand Alone Atrial Fibrillation -- Over fifteen US centers have

performed stand-alone ablation using the existing ATS CryoMaze

products. These efforts include a study at East Carolina University

where 57 patients have been treated for atrial fibrillation using ATS

CryoMaze through minimally invasive access. The results of the study

demonstrate over 90% freedom from atrial fibrillation at six months.

Tissue Heart Valves

-- ATS 3f(R) Aortic Bioprosthesis: The Company's first generation tissue

valve has been approved for sale in Europe and Canada and launch

activities in these geographies are underway. The ATS 3f Aortic

Bioprosthesis represents the Company's first product targeted at the

largest market in cardiac surgery, tissue heart valves.

As announced previously, the Food and Drug Administration (FDA) has

asked ATS to provide additional information and clarification in

support of its PMA for the ATS 3f Aortic Bioprosthesis. The request

relates primarily to in-vitro testing submitted in the original IDE

application. The Company intends to work collaboratively with the FDA

to answer all questions early in 2008. Management remains confident

that the ATS 3f Aortic Bioprosthesis has met or exceeded all of the

requirements and is approvable, but it is now anticipated in the

second half of 2008.

-- ATS 3f Enable(TM) Aortic Bioprosthesis: Enrollment in the Company's

European clinical trial of its Enable tissue valve designed to provide

a less invasive approach for aortic valve replacement continues to

progress with excellent clinical results. The Company expects to

reach enrollment of 100 patients in the pivotal stage of the trial

around mid year, and anticipates its first regulatory approval for

commercialization in 2009.

Mechanical Valves

-- ATS Open Pivot AP360(TM) Mechanical Heart Valve: The Company received

FDA approval of its ATS AP360 Heart Valve in December 2007. The AP360

is the Company's most competitive Open Pivot product, with the same

hemodynamic features as its existing supra annular AP valve but with a

revised cuff design to enable easier suturing. A limited launch has

begun and initial physician experience has been extremely positive.

The Company is currently building inventory in preparation for a wider

launch in the second quarter.

Repair Products

-- ATS Simulus(R) Semi-Rigid and Adjustable Flexible Rings: Initial

launch and implants have been completed and surgeon feedback has been

very positive. Both rings have been designed to be easily used with

the da Vinci(R) robotic system from Intuitive Surgical (Traded on the

NASDAQ stock exchange under the symbol "ISRG") and minimally invasive

repair techniques. Because of the ease of suture placement, the ATS

Simulus Flexible rings and bands are fast becoming the annuloplasty

device of choice among surgeons performing surgical robotic mitral

valve repair.

"We finished 2007 with good momentum and a strong product pipeline that will continue to drive our growth in 2008," continued Mr. Dale. "Our new development efforts have produced innovative new products designed specifically to improve efficacy for the cardiac surgeon and safety for their patients. As a result, we have made substantial progress on several key milestones -- diversifying our revenue sources, leveraging our sales force and enhancing our profit potential. We believe 2008 will be another landmark year for ATS and we look forward to continued growth and enhanced financial performance."

Additional Financial Results

The operating loss for the fourth quarter was $4.9 million compared with an operating loss of $5.6 million in the fourth quarter of 2006. The net loss for the 2007 fourth quarter was $6.2 million, or $0.10 per share, compared with $6.1 million, or $0.15 per share in the fourth quarter of 2006.

Full Year 2007 Results

For the full year 2007, revenue totaled $49.6 million, 22.6% above 2006 revenue of $40.4 million. The Company reported a net loss for 2007 of $23.0 million, or $0.44 per share, compared to a net loss of $27.7 million, or $0.83 per share, in 2006. The net loss for 2007 included charges for acquired in-process research and development of $3.5 million related to the CryoCath asset acquisition and $0.8 million related to discontinuance of the PARSUS development program. The net loss for 2006 included a charge for acquired in-process research and development of $14.4 million related to the acquisition of 3f Therapeutics.

2008 Outlook

For the full year 2008 the Company expects revenue to grow approximately 21% to 29% from 2007 to a range of $60 to $64 million. The Company continues to expect to generate a profit in the fourth quarter of 2008.

Conference Call Today

ATS management will host a conference call today, February 25, 2008 at 5:00 p.m. ET to discuss its fourth quarter financial results and current corporate developments. The dial-in number for the conference call is 800-218-4007 for domestic participants and 303-262-2142 for international participants. A live webcast of the call can also be accessed at by clicking on the Investors icon.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 800-405-2236 for domestic participants and 303-590-3000 for international callers, using the passcode 11109130#.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2006 and its most recent quarterly report on Form 10-Q.

ATS Medical, Inc.

Condensed Consolidated Statements of Operations

(in thousands except per share amounts)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Net sales $14,217 $10,740 $49,587 $40,449

Cost of goods sold 5,937 5,266 21,348 19,568

Gross profit 8,280 5,474 28,239 20,881

Operating expenses:

Sales and marketing 7,019 5,851 24,633 21,008

Research and

development 2,173 2,011 7,546 3,381

In-process research

and development - - 3,500 14,400


termination expense - 657 - 733

General and

administrative 3,099 2,498 10,417 8,786

Amortization of

intangibles 885 106 2,516 106

Intangible asset

impairment - - 755 -

Total operating

expenses 13,176 11,123 49,367 48,414

Operating loss (4,896) (5,649) (21,128) (27,533)

Interest expense, net (555) (434) (1,822) (1,669)

Other income

(expense) (594) 3 61 1,528

Net loss before

income taxes (6,045) (6,080) (22,889) (27,674)

Income tax expense 116 - 119 -

Net loss ($6,161) ($6,080) ($23,008) ($27,674)

Net loss per share:

Basic and diluted ($0.10) ($0.15) ($0.44) ($0.83)

Weighted average

number of shares


Basic and diluted 59,412 40,304 52,589 33,537

ATS Medical, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

December 31, December 31,

2007 2006


Cash and short-term investments $14,669 $10,704

Accounts receivable 11,186 11,677

Inventories 18,743 18,782

Prepaid expenses 1,143 1,175

Total current assets 45,741 42,338

Property and equipment, net 7,739 8,213

Intangible assets 50,779 33,155

Other assets 1,638 2,134

Total assets $105,897 $85,840

Liabilities & shareholders' equity

Accounts payable $4,794 $3,183

Accrued compensation 2,361 2,589

Other accrued liabilities 2,000 2,457

Current maturities of bank notes payable 2,457 1,133

Warrant liability 3,913 -

Total current liabilities 15,525 9,362

Convertible senior notes payable 17,436 17,394

Bank notes payable 6,143 1,194

Payable to CryoCath Technologies Inc. 1,742 -

Deferred income taxes 95 -

Shareholders' equity 64,956 57,890

Total liabilities & shareholders' equity $105,897 $85,840

ATS Medical, Inc.

Consolidated Condensed Statements of Cash Flow

(in thousands)

Year Ended December 31,

2007 2006

Operating activities

Net loss ($23,008) ($27,674)

Adjustments to reconcile net loss to net cash

used in operating activities:

Depreciation and amortization 4,622 1,924

Loss on disposal of equipment - 26

Stock compensation expense 1,454 1,103

Acquired in-process research and development 3,500 14,400

Impairment of intangibles 755 -

Deferred income taxes 95 -

Non-cash interest expense 546 463

Change in value of common stock appreciation

rights and convertible senior notes

derivative liabilities 554 (1,528)

Changes in operating assets and liabilities 1,939 1,456

Net cash used in operating activities (9,543) (9,830)

Investing activities

Maturities (purchases) of short-term

investments, net 1,903 (990)

Acquisition of assets of CryoCath

Technologies Inc. (21,074) -

Business acquisition costs,

net of cash acquired (1,791) (717)

Payments for technology licenses

and other intangibles (277) (521)

Purchases of furniture, machinery

and equipment (748) (1,208)

Other (36) -

Net cash used in investing activities (22,023) (3,436)

Financing activities

Advances on bank notes payable 8,600 1,500

Repayments on bank notes payable (2,327)

SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
(Date:11/30/2015)... ... , ... According to Los Angeles bariatric surgeon Michael Feiz, M.D., F.A.C.S., many ... real hunger, but instead by a hormone called ghrelin which (often prematurely) signals ... are aware that weight loss surgery can help patients lose weight by restricting the ...
(Date:11/30/2015)... Miami, FL (PRWEB) , ... November 30, 2015 ... ... added a comparison chart and ingredient list of its hemorrhoid ointment to its ... “fast, effective pain relief for people suffering from hemorrhoids. Adding the comparison chart ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood sugar tests ... adults, according to a new study by researchers at the School of Public Health ... Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently ... Poison Data System (NPDS) reveals that in 2014, someone called a poison center ... two million of which were human exposure cases. , The American Association of ...
(Date:11/30/2015)... Reading, PA (PRWEB) , ... November 30, 2015 ... ... Ashland Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties ... supplements markets in the US, effective immediately. , “We are pleased to ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
(Date:11/30/2015)... CHICAGO , Nov. 30, 2015   Nuance ... The National Decision Support Company (NDSC) today ... support and collaboration capabilities that utilize the American College ... and healthcare provider organizations to comply with current ... --> --> By combining clinical ...
(Date:11/30/2015)... , Nov. 30, 2015 Varian Medical Systems (NYSE: ... an educational partnership with Apollo Hospitals Group, the largest hospital chain ... will help train radiation technologists in the country. The MoU was ... Apollo Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its ...
Breaking Medicine Technology: